Pharma-Bio Serv, Inc. 8-K

What Happened Pharma-Bio Serv, Inc. filed an 8-K reporting the results of its May 15, 2026 Annual Meeting of Stockholders. Irving Wiesen was elected as a Class I director to serve until the 2029 Annual Meeting (or until his successor is duly elected). The company’s stockholders also ratified the selection of Crowe PR PSC as the independent certified public accountants for the fiscal year ending October 31, 2026.

Key Details

• Irving Wiesen election: 10,208,071 votes for; 195,625 votes withheld. There were 2,839,645 broker non-votes on this proposal.
• Auditor ratification: 13,241,794 votes for; 31,544 votes against. There were no broker non-votes on the auditor ratification.
• Meeting date: May 15, 2026. Auditor engagement covers fiscal year ending October 31, 2026.

Why It Matters

• Board composition: Electing Wiesen fills a Class I director seat and affects the company’s governance through the 2029 Annual Meeting.
• Audit continuity: Ratifying Crowe PR PSC confirms who will audit Pharma-Bio Serv’s financial statements for the coming fiscal year, which is relevant for financial reporting reliability.
• Voting dynamics: The substantial number of broker non-votes on the director election (2.84M) means many shares held by brokers were not voted on that item, which can affect the vote outcome and indicates varying investor participation across proposals.